Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
View Patent ↗The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.
1. A method for treating aseptic liver tissue injury inflammation in a subject comprising administering to the subject:
(a) a CD24 agonist;
(b) a Siglec-10 agonist; and
(c) an anti-HMGB1 antibody antagonistic to HMAB-1;
wherein the CD24 agonist comprises
a CD24-Fc fusion protein;
and
wherein the Siglec-10 agonist comprises an anti-Siglec-10 antibody.
2. The method of claim 1 , wherein the administering includes parenteral administration.
3. The method of claim 1 , wherein the administering further comprises an excipient.